Skip to Main content Skip to Navigation
Journal articles

Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis.

Abstract : Tocilizumab is a humanized antibody against the membrane and soluble receptors for interleukin-6. Tocilizumab is among the disease-modifying antirheumatic drugs (DMARDs) used to treat moderate-to-severe active rheumatoid arthritis (RA) refractory to conventional DMARDs. We report a case of macrophage activation syndrome that complicated acute hepatitis E and started within 24hours after the fourth tocilizumab infusion in a patient with RA.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134354
Contributor : Laurent Jonchère <>
Submitted on : Monday, March 23, 2015 - 2:36:54 PM
Last modification on : Wednesday, April 1, 2020 - 4:58:04 PM

Identifiers

Citation

Marie Leroy, Guillaume Coiffier, Charlotte Pronier, Louise Triquet, Aleth Perdriger, et al.. Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis.. Joint Bone Spine, Elsevier Masson, 2015, 82 (4), pp.278-279. ⟨10.1016/j.jbspin.2015.01.018⟩. ⟨hal-01134354⟩

Share

Metrics

Record views

112